Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of oncological and functional outcomes

Background We evaluated clinical outcomes of region target focal therapy with high-intensity focused ultrasound (HIFU) for the localized prostate cancer (PCa) based on magnetic resonance imaging-based biopsy and systematic prostate biopsy for Asian. Methods We prospectively recruited patients with l...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2020-10, Vol.25 (10), p.1844-1853
Main Authors: Shoji, Sunao, Hiraiwa, Shinichiro, Uemura, Kohei, Nitta, Masahiro, Hasegawa, Masanori, Kawamura, Yoshiaki, Hashida, Kazunobu, Hasebe, Terumitsu, Tajiri, Takuma, Miyajima, Akira
Format: Article
Language:English
Subjects:
Biopsy
Cancer Research
Catheterization
Ejaculation
Erectile dysfunction
Localization
Magnetic resonance imaging
Medicine
Medicine & Public Health
Oncology
Original Article
Patients
Prostate cancer
Quality of life
Surgical Oncology
Tumors
Ultrasonic imaging
Ultrasound
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We evaluated clinical outcomes of region target focal therapy with high-intensity focused ultrasound (HIFU) for the localized prostate cancer (PCa) based on magnetic resonance imaging-based biopsy and systematic prostate biopsy for Asian. Methods We prospectively recruited patients with localized PCa, located their significant tumors using MRI-transrectal ultrasound (TRUS) elastic fusion image-guided transperineal prostate biopsy and 12-cores transperineal systematic biopsy, and focally treated these regions in which the tumors were located in the prostate using HIFU. Patients’ functional and oncological outcomes were analyzed prospectively. Results We treated 90 men (median age 70 years; median PSA level 7.26 ng/ml). Catheterization was performed within 24 h after the treatment in all patients. Biochemical disease-free rate was 92.2% during 21 months follow-up when use of Phoenix ASTRO definition. In follow-up biopsy, significant cancer was detected in 8.9% of the patients in un-treated areas. Urinary functions, including international prostate symptom score (IPSS) ( P  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-020-01723-9